RBC Capital, BofA up Agios targets after FDA Priority Review acceptance of mitapivat for sickle cell

 

RBC Capital and BofA raise Agios targets after FDA Priority Review acceptance of mitapivat for sickle cell disease

• RBC Capital raised its Agios price target to $32 and BofA to $46 after mitapivat Priority Review acceptance
• FDA accepted mitapivat sNDA for sickle cell disease and granted Priority Review, with PDUFA target date November 1, 2026

https://finviz.com/stock?t=AGIO&p=d